Notably, those studies elucidated the different spectrum of NS‐causing and leukemia‐associated mutations, suggesting a differential quantitative perturbing effect of the two classes of mutations in upregulating SHP2's function and RAS‐MAPK signaling. The gene discussed is PTPN11; the disease is leukemia.